Dr. Benjamin Maughan, MD
Claim this profileFarmington Health Center
Studies Cancer
Studies Bladder Cancer
9 reported clinical trials
16 drugs studied
Area of expertise
1Cancer
Stage IV
PD-L1 positive
hCG positive
2Bladder Cancer
Stage III
PD-L1 positive
Stage IV
Affiliated Hospitals
Clinical Trials Benjamin Maughan, MD is currently running
Immunotherapy + Radiation ± PARP Inhibitor
for Prostate Cancer
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.
Recruiting1 award Phase 2
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
More about Benjamin Maughan, MD
Clinical Trial Related7 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Benjamin Maughan, MD has experience with
- Nivolumab
- Pembrolizumab
- Cabozantinib S-malate
- Atezolizumab
- Carboplatin
- Oxaliplatin
Breakdown of trials Benjamin Maughan, MD has run
Cancer
Bladder Cancer
Prostate Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Benjamin Maughan, MD specialize in?
Benjamin Maughan, MD focuses on Cancer and Bladder Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Benjamin Maughan, MD currently recruiting for clinical trials?
Yes, Benjamin Maughan, MD is currently recruiting for 2 clinical trials in Farmington Utah. If you're interested in participating, you should apply.
Are there any treatments that Benjamin Maughan, MD has studied deeply?
Yes, Benjamin Maughan, MD has studied treatments such as Nivolumab, Pembrolizumab, Cabozantinib S-malate.
What is the best way to schedule an appointment with Benjamin Maughan, MD?
Apply for one of the trials that Benjamin Maughan, MD is conducting.
What is the office address of Benjamin Maughan, MD?
The office of Benjamin Maughan, MD is located at: Farmington Health Center, Farmington, Utah 84025 United States. This is the address for their practice at the Farmington Health Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.